Jul 1, 2020 · The PE level of soluble CDH3 (sCDH3) was increased in patients with resistance. The altered sCDH3 serum level reflected the efficacy of EGFR-TKI after 1 month of treatment ( n = 43). Baseline sCDH3 was significantly associated with PFS and OS in patients with ADC after EGFR-TKI therapy ( n = 76).

Jul 1, 2020 · By integrating PE proteomic and tissue genomic analyses, we herein identified soluble cadherin-3 (sCDH3) as a marker for monitoring first/second-generation EGFR-TKI resistance in real time. Cadherin-3 (CDH3) knockdown …

Dec 8, 2023 · Down-regulation of CDH3 enhances the sensitivity of LUAD cell lines to EGFR-TKIs. The baseline serum-soluble CDH3 level has been correlated with progression-free survival (PFS) of LUAD patients receiving EGFR-TKI treatment and the OS of NSCLC patients.

Nov 15, 2021 · CDH3, a cell adhesion molecule, is associated with the function of cells to bind with other cells and the extracellular matrix (ECM). CDH3 is overexpressed in many malignancies (Kaupmann et al., 1992). In our study, it was also found to be overexpressed in EGFR-MT LUAD.

Abnor-mal expression of CDH3 is associated with a poor prognosis in patients with breast, thyroid, colorectal carcinomas and glioblastoma. Soluble CDH3 in pleural efusions can be used as a marker for real-time monitoring of resistance to first- and second-generation EGFR-TKIs.

Abnormal expression of CDH3 is associated with a poor prognosis in patients with breast, thyroid, colorectal carcinomas and glioblastoma. Soluble CDH3 in pleural effusions can be used as a marker for real-time monitoring of resistance to first- and second-generation EGFR-TKIs.

We aimed to iden- Results: Fifteen proteins were identified as potential biomarkers tify biomarkers to monitor and predict the progression of of EGFR-TKI resistance. Cadherin-3 (CDH3) was overexpressed in patients receiving EGFR-TKIs via a comprehensive omic ADC tissues compared with normal tissues.

BC3195 is known as the only ADC in clinical stage, targeting CDH3 with payload of MMAE. A phase I, open-label, first in human study to evaluate the safety, tolerability, PK, and preliminary antitumor activity of BC3195 is being performed in patients …

Dec 31, 2022 · Expression of CDH3 is an indicator of poor prognosis in human breast cancer and a marker for real-time monitoring of resistance to first/second generation EGFR-TKIs. In this present manuscript, we describe that high CDH3 expression is correlated with shorter overall survival of patients in lung adenocarcinomas and low CDH3 expression inhibits ...

EGFR, fibrillin-2, P-cadherin and AP2beta as biomarkers for rhabdomyosarcoma diagnostics. Aberrant demethylation of CDH3 is associated with colorectal carcinomas. Expression of CD24, P-cadherin and S100A4 in tumors of the ampulla of Vater.